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resumo 
 
 
O presente trabalho propõe apresentar as principais atividades de um 
Enfermeiro de investigação, o seu papel em investigação clínica, no 
desenvolvimento e na introdução de novos medicamentos no mercado. 
O Mestrado em Biomedicina Farmacêutica permitiu reunir conhecimentos e 
desenvolver novas competências técnicas e pessoais de extremo valor na 
atividade diária, como enfermeira de investigação. 
No decorrer da minha atividade profissional como Enfermeira de investigação, 
foram detetadas muitas lacunas na formação académica e profissional dos 
enfermeiros, no que diz respeito a esta área específica. 
Pretendo apresentar uma visão pessoal, descrevendo as principais atividades 
desenvolvidas e como os conhecimentos adquiridos neste Mestrado 
influenciaram o meu desempenho profissional. 
O principal objetivo deste trabalho é constituir uma referência ou guia para 
outros enfermeiros que queiram enveredar pela área da investigação clínica. 
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abstract 
 
This paper proposes to present the main activities of a Research Nurse, its role 
in clinical research, and in the development and introduction of new drugs on 
the market. 
The Master in Pharmaceutical Medicine brought together knowledge and 
development of new technical and personal skills extremely valuable in daily 
activity as research nurse. 
During my professional activity as a research nurse, were detected many gaps 
in academic and professional training of nurses, with regard to this specific 
area. 
I intend to present a personal view, describing the main activities developed 
and how the knowledge acquired in this Master influenced my work 
performance. 
The main objective of this work is to provide a reference or guide to other 
nurses who want to enter into the area of clinical research. 
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1. INTRODUCTION 
 
The world of clinical research is developing in a quick way, it is therefore urgent to promote 
the development and education of professionals who participate in it.  
It is extremely important that professionals working in this field have the best qualifications 
because are they who will test drugs and collect data for further analysis, without forgetting 
that the safety of participants (sick or not) is above any value. The training course in 
Pharmaceutical Medicine plays an important role in promoting the education of health 
professionals, covering all aspects of drug development, from discovery to post-marketing 
phase. 
Nurses play an important role in clinical research, assuring participant safety, implementation 
and conduction of the protocol and ongoing maintenance of informed consent, all within the 
context of effective and appropriate clinical care. It is critical that investigators, sponsors of 
clinical research, health policy makers and regulators have an understanding of this important 
role. 
The present work pretends to describe the clinical practice of a research nurse, describing the 
necessary skills, responsibilities and main activities in this area. In order to be easy to follow, it 
will be done a link to the theoretical knowledge, making an overview of Research and 
Development (R&D) of medicinal products and the current perspective of clinical research in 
Portugal. 
My personal experience in this area as research nurse and all my educational and professional 
background will be displayed in this work. 
My expectations for this work focus on the possibility of, in the future, be an “inspiration” to 
nurses that want to follow a career in Clinical Research. 
 
1.1 OBJECTIVES 
 
The objective of this work is to structure and define the duties and responsibilities of a research 
nurse, listing the main personal and technical competences needed to develop in the daily 
 2 
 
practice. It also pretends to present the main activities of a research nurse, its role in clinical 
research, and in the development and introduction of new medicinal products on the market. 
The development of this work aims to be a guide for nurses who want to work in the field of 
clinical research, or who knows, be a starting point to the beginning of a new nursing specialty. 
  
1.2 PROFESSIONAL BACKGROUND 
 
Besides the theoretical knowledge obtained in the training Program of Pharmaceutical 
Medicine, my professional background through the different services and institutions where I 
worked gave me huge knowledge and clinical practice, which could only be accumulated over 
the years. The 19 years of experience were fundamental in the acquisition of all clinical 
information that I gathered as well as the acquisition of personal and technical skills, 
fundamental in the activity that I currently perform in the clinical research area. This skills and 
competences will be described later as the core competencies necessary to research nurse 
activity. 
Next, it is presented the journey through the different services/institutions and the key skills 
acquired in each of them. 
 
HOSPITAL DE SÃO JOÃO 
In 1995, I started my professional career in Hospital de São João, a central hospital, in Adult 
Emergency Service, where I worked for eleven years. In this service I had the opportunity to 
work with several medical and surgical specialties, gathering knowledge in different areas, 
learning to act in an accurate and precise way, because in emergency situations speed is friend 
of perfection and minutes can make the difference between life and death. 
In 1997, I started working at pre-hospital emergency service, in the Emergency and 
Resuscitation Medical Car (VMER), until 2014. In this service, the team is composed by a 
physician and a nurse, and in this activity we take emergency care out of the hospital to the 
patient's home, to the street or to the scene of the incident. We learn to be autonomous, 
flexible, multifaceted and to improvise, often in adverse situations. 
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In 2006, I decided to learn more in another area and I changed to oncology, specifically, 
hemato-oncology service, where I stayed for eight years. In this service I acquired knowledge 
on hemato-oncology diseases, autotransplant, chemotherapy treatments and development of 
human relationship with the patient, since confinements are longer and the patient can be 
contextualized in their social and family reality. 
In Hospital de São João did not have experience with clinical trials, but all the clinical 
knowledge gained in these 19 years of experience were fundamental in the performance of my 
current professional activities as a research nurse. 
 
BIAL 
My contact with clinical research happen in 1999, when I started working at part-time as 
research nurse in the Human Pharmacology Unit of Phase I, at a Portuguese pharmaceutical 
company named Bial. The Phase I Unit was composed by 6 beds with cardio-respiratory 
monitoring. At this time my knowledge of clinical trials were very limited. The nursing 
academic training did not include any education or training in clinical trials or clinical 
research. 
As phase I research nurse, I performed the clinical procedures required by Protocol, and at the 
same time I was increasing my knowledge in this area. Besides working as research nurse, I 
also coordinated the nursing team, until I become Research Nurse Coordinator (RNC). I also 
cooperated in the performance of the working plans, managing supplies and equipment, 
assuring its good conditions, maintenance and stock. I was responsible for elaboration of 
clinical Standard Operating Procedures (SOP´s). 
I've been involved in the elaboration of structural plan of the new Human Pharmacology Unit 
of Bial, composed by 20 beds, 10 of these with cardio-respiratory monitoring, and in the 
selection of the necessary equipment to the normal operation of the Unit. During this time, I 
had the opportunity of monitoring some phase I clinical studies.  
In this Phase I unit, I participated in several clinical trials in healthy volunteers, including 
bioavailability and bioequivalence studies, drug-drug interactions, effect of food and dosage 
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form proportionality, entry-into-man and special populations, having the opportunity to 
collaborate in the clinical development of six new chemical entities. 
 
1.3 HOSTING INSTITUTION 
 
I started to work at Blueclinical, as RNC, in 2013. Blueclinical is a Portuguese Clinical 
Research Company founded in 2012. The purpose of Blueclinical is generate value for society, 
through effectiveness and therapeutics innovation, and conduct clinical research according all 
applicable ethical, scientific and regulatory requirements. 
This company is divided into three business units, providing services covering different phases 
of drug discovery process, from bench to bedside: Blueclinical R & D consultancy, 
Blueclinical Clinical Research Partnership (CRP) and Blueclinical Phase I. 
The mission of Blueclinical R&D is to promote the development of translational medicine 
projects and support other companies and institutions, especially start-ups, in the development 
of their R&D projects with the goal of market introduction. This business unit provide advice 
in development plans of new drugs, medical devices and other health products, during all the 
development phases - pharmaceutical, preclinical, clinical and regulatory. It also support in 
preparation of scientific advice, preparation of investigator brochure, investigational medicine 
dossier, business development plan, portfolio selection and funding application 1. 
Blueclinical CRP was created to provide support to clinical research activity in study sites 
promoting mutual growth, efficiency and quality in the conduct of studies, with medicinal 
products and medical devices. 
The CRP network is growing in hospitals and primary care units, providing organized and 
expert research teams focused on complying with quality standards, ethical and legal 
requirements. The growing efficiency and quality provide an excellent reputation of clinical 
research centers 2. 
Blueclinical Phase I was inaugurated in 2013, the mission is to conduct phase I studies in 
healthy subjects and early stage studies (proof-of-concept) in selected patient populations, in 
full compliance with international regulations 3. 
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The experience as research nurse at Blueclinical Phase I Unit will be developed further on in a 
more detailed manner. 
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2. STATE-OF-THE-ART 
 
The clinical research plays a central role in generating new knowledge and turn the scientific 
discoveries useful to society through the drug development processes. The main objective of 
this chapter is to give an overview of the pertinent items related with clinical research and the 
key points of drug development process.  
 
2.1 R&D OF MEDICINAL PRODUCTS 
 
The development of a new medicinal product, from the original idea to the finished product, 
can take a long and complex process of about 10-15 years. The estimated cost to research and 
develop each successful drug is around $800 million to $1 billion. This amount includes the 
cost of the thousands of failures. For each 5,000-10,000 compounds in R&D just one receive 
approval 4. 
With the knowledge of the human genome, scientists hope to discover new drugs that 
specifically and powerfully can prevent and cure diseases. 
The different stages of Research & Development process are represented in Figure 1.  
 
 
 
Figure 1- Stages of pharmaceutical R&D 5.  
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Discovery phase 
In the development of medicinal products the main objectives are to demonstrate that the new 
entity has a constant chemical quality, is effective in a significant number of patients and most 
of all is safe. The original idea could come from academics, clinical research or even 
commercial sector, and includes a profound understanding of the disease and their causes.   
Researchers work to reconstruct the basic causes of disease at the level of genes, proteins and 
cells. This information allow recognise “targets” which could be affected by potential new 
medicinal drugs. When a target is selected, “target discovery”, it starts a process to identify 
molecules which have appropriate characteristics to create suitable medicinal products. These 
molecules should be capable to interact with the selected target and cause the desired effect 
“target validation” 6.  
The knowledge of the disease, allow scientists to begin search for a molecule, or “lead 
compound” that may act on their target and modify the disease development. The “lead 
compound” will pass through a series of tests, in living cells, in animal models of disease and 
computational models, to determine which compound are suitable to continue. This tests assess 
the safety and efficacy of the compound, testing pharmacokinetics, pharmacodynamics and 
toxicological properties of each one 7. 
The drugs that pass the initial screening will suffer an optimization, “lead optimization”, to 
become more effective and safer. Scientists change their structure given it different properties, 
for example, they can reduce the possibility of interaction with other substances, reducing by 
this way the potential of causing side effects. At this stage, researchers begin to think about 
development methods for purifying, formulating, manufacturing, and testing the product 
candidate 7. 
The objective of the final drug discovery phase is to preserve favourable properties in 
compounds while others are improved. 
 
Non-clinical studies 
After the discovery phase, scientists carry out in vitro and in vivo tests extensively to 
understand the action and safety profile of the drug, to decide if they should move on to testing 
in humans. 
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Several pre-clinical preliminary studies will have to be conducted in order to collect 
information to support the conduct of clinical trials and all progress until marketing approval 
by regulatory authorities. These tests include in vitro and in vivo studies, and most recently in 
silico studies. These tests can help to decide how to proceed to the next clinical development 
phase and are essential to primarily understand the potential success of the drug 8. 
The various safety studies, from those that are necessary to evaluate the risk of exposing the 
first human to those required by regulatory authorities in order to market a medicine, are 
essential elements of a fundamental International Conference on Harmonization (ICH 
guideline, Guidance on Non-clinical Safety Studies for the Conduct of Human Clinical Trials 
and Marketing Authorization for Pharmaceuticals 9. Different studies are required for each 
development phase. In these studies is extremely important to take into account that may exist 
qualitative and quantitative differences in biological responses in animals compared to 
humans. In practice this means that non-clinical animal studies may not reproduce the intended 
pharmacological effect in humans, may give an incorrect interpretation of pharmacokinetic 
results and may not identify relevant toxic effects. 
The information obtained in non-clinical studies is used to estimate a safe starting dose and 
doses range for clinical trials 9. 
In order to bring a new medicinal product to the market, Sponsors have to demonstrate its 
efficacy, quality and safety with a several types of clinical trials. 
During this stage researchers start to work in the first scale up of the drug, techniques to 
translate the small scale of a lab to larger production, to make large quantities of the drug for 
clinical trials 4. 
 
Clinical Trials 
Before the beginning of a clinical trial important information will be evaluated by Competent 
Authorities and Ethics Commission to assure that subjects who participate in the clinical trials 
will not be exposed to unreasonable risks. 
The results of the preclinical work, the chemical structure of the candidate drug and how it is 
supposed to work in the body, side effects and manufacturing information, will be evaluated. 
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The complete clinical trials plan, including how, where and whom will perform the studies, 
also will be a focus of attention. Experts will review all the information to determine if the 
medicine reveals to be sufficient safe and effective to be approved. 
Traditionally, clinical trials have been divided in four phases:  
 
Phase I or Human Pharmacology Studies  
The candidate drug is tested for the first time in humans. The testing is performed in small 
groups of healthy volunteers, about 20 to 100 subjects 10,11. 
The objective is determine drug safety and tolerability in humans. The researchers study the 
pharmacokinetics (PK) and the pharmacodynamics (PD) profile and identify side effects 10,11. 
PK and PD studies may be conducted in healthy volunteers or in patients with the target 
disease. 
This trials are carefully monitored and help researchers to find the safe dosage range and help 
him to decide to move on to additional development. 
 
Phase II or Therapeutic Exploratory Studies 
In this phase the drug candidate is tested in a small group of patients, about 100 to 500 patients 
with the disease or condition to be studied 10,11. 
The drug candidate is evaluated for therapeutic efficacy, potential short-term side effects 
(adverse events), and risks associated with the drug 10,11.  
The researchers can estimate the dosage and regimen for following studies, and define the 
preliminary tolerability/safety profile in patients. 
Clinical trial Phase II sometimes are divided into: 
Phase IIa  
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Pilot clinical trials to evaluate efficacy (and safety), dose range exploration or proof of concept 
in selected populations, could be conducted in patients or healthy volunteers 10,11.  
 Phase IIb 
Well controlled pivotal trials to evaluate efficacy (and safety) and dose finding in patients with 
the disease or condition to be treated 10,11.  
 
Phase III or Therapeutic Confirmatory Studies 
Phase III studies begin if evidence of effectiveness is shown in Phase II. These studies collect 
more information about safety and effectiveness of the drug candidate, compare it to 
commonly used treatments. This studies are made in a larger number of patients, about 1,000-
5,000, to generate statistically significant data 10,11. 
Different populations, different dosages and different combination with other drugs are studied 
in this phase. It also provides important data that can be used to support adequate instructions 
for use of the drug. 
Phase III trials are the most expensive and longest trials. These studies are intended to provide 
a satisfactory foundation for marketing approval. 
 
Phase IV or Therapeutic Use 
This studies occurs after marketing approval, in a large number of patients that begin to use the 
medicinal product, providing information about therapeutic effectiveness in real life conditions 
and optimisation of the drug's use 10,11. 
Pharmaceutical companies should continue to monitor the medicinal product, including long-
term safety and adverse events (AE). 
The traditional R&D model represents high costs, slowness, high failure rates, and 
inefficiency, meaning increasing investments vs decreasing new drugs in the market. 
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The traditional paradigm of drug development contrasts with alternative development 
paradigm referred to as "quick win, fast fail" (Figure 2). 
 
 
 
Figure 2 - Paradigm of drug development "quick win, fast fail” 12. 
 
 
In this new paradigm, technical uncertainty is decreased before moving on to more advanced 
and quite expensive phases such as phase II and III.  
The proof of concept (PoC) is the earliest point in the drug development process. It allows 
assessing the usefulness and effectiveness of a new molecule and establish the safety of drug 
candidates in the target population. This test should involve a small number of subjects and 
should be performed earlier in clinical development, preferably in phase I. 
With this new paradigm, there is a reduction of new molecular entities moving to Phase II and 
III, but that progress has higher probability of success. PoC is a landmark in the decision to 
proceed with the remaining clinical development of a drug 12. 
The savings achieved by suppression of the later stages of development, which would result in 
failure, are reinvested, increasing productivity, selection of new entities, conducting the first 
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dose efficacy and first human dose, and developing a new product. These measures allow drug 
developers to make "Go/No Go" decisions about proceeding with larger and more expensive 
studies enabling save time and money 12. 
Bioequivalence (BE) and Bioavailability (BA) studies and Generic Drugs 
Pharmaceutical development is a long and expensive process. Pharmaceutical patents 
registering can be done during any phase of drug development. In most countries of the world, 
patent protection expire 20 years from the date of registering. However, some countries, as 
USA, grant additional protective measures as Exclusivity. This additional measure is an 
exclusive marketing right granted by the FDA. Exclusivity is granted upon approval of a drug 
product and was designed to promote a balance between new drug innovation and generic drug 
competition 13.     
A generic drug is produced and distributed without patent protection. The generic drug may 
still have a patent on the formulation but not on the active ingredient 
A generic drug must contain the same active ingredient as the original formulation, must be 
identical in dose, strength, route of administration, safety, efficacy, intended use and must 
demonstrate bioequivalence with the reference medicinal product, by appropriate 
bioavailability studies. Safety and efficacy studies are already known from the approved 
product, and it would be unethical to subject research participants to clinical studies just to 
prove information that already exists 14.  
Bioavailability refers to the rate and extent to which the active pharmaceutical ingredient 
(API), or its active moiety, is absorbed from a pharmaceutical product and becomes available 
at the site of action 15. 
Bioequivalence is defined as the absence of a significant difference in bioavailability between 
two pharmaceutically equivalent products or pharmaceutical alternatives under similar 
conditions in an appropriately designed study 15. 
The recommended standard design to compare two formulations is a randomised, two-period, 
two-sequence single dose crossover study. The wash out period to separate the treatment 
periods should be sufficient to ensure that at the start of the second period, drug concentrations 
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are below the lower limit of bioanalytical quantification in all subjects. Usually, to achieve this 
are necessary at least 5 elimination half-lives 16. 
The number of evaluable subjects in a BE study should be based on an appropriate sample size 
calculation and should not be less than 12 16. 
The test conditions should be standardized to minimize variability except for the products to be 
tested. So it is recommended to standardize diet, fluid intake and exercise. Usually, a 
bioequivalence study should be conducted under fasting conditions, however if the Summary 
of Product Characteristics (SmPC) recommends intake the reference medicinal product only in 
fed state, the bioequivalence study should be conducted under fed conditions. The meal should 
be a high-fat and high-calorie meal 16,17. 
A sufficient number of samples should be collected to describe appropriately the plasma 
concentration-time profile. In studies to determine bioequivalence after a single dose should be 
determined area under the plasma concentration versus time curve (AUC) from time zero to 
the last sampling time with quantifiable concentrations (AUC0-t), AUC from time zero to 
infinity (AUC0-∞), residual area, maximum observed plasma concentration (Cmax) and time of 
occurrence of Cmax (tmax) 
16,17,18. These parameters are graphically represented in Figure 3.  
 
 
 
Figure 3 - Representation of relevant parameters in bioequivalence studies 19. 
 
In bioequivalence studies, the plasma concentration time curve is generally used to assess the 
rate and extent of absorption. For these parameters the 90% confidence interval for the ratio of 
Drug A - reference product (innovator product) 
Drug B - generic product 
Cmax - maximum plasma drug concentration 
Tmax - time required to achieve a maximal concentration 
AUC - total area under the plasma drug concentration-time 
curve 
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the test and reference products should be contained within the acceptance interval of 80.00-
125.00%. Products meeting the bioequivalence requirements can reliably be assumed to 
produce similar clinical effects when used interchangeably in the same patient 18,20. 
Sometimes it is stated that the 80 to 125% limit means there can be a 45% variation between 
the generic and the reference product, but this is not really the case. The average is usually 
close to 100% and this is the value of maximum likelihood for the comparison. 
Bioequivalence studies are growing due to the faster process of drug development and to the 
very competitive prices (30-60% lower) comparatively with Reference products. 
In the generic drugs development is important to maintain a demanding regulation, in order to 
keep the high quality standards as is required to reference products. 
 
2.2 CLINICAL TRIALS IN PORTUGAL 
 
Regulatory environment in Portugal is constituted by national regulations and transpositions of 
European Directives. All These regulations lead to a complex and slow submission process.  
The conduction of a clinical trial in Portugal has to be previously authorized by the Competent 
Authorities. The Portuguese National Authority for Medicines and Health Products 
(INFARMED) is responsible for evaluating the risk and benefit of the clinical trial and to 
authorize its conduction. It is also required an approval of the Ethics Commission for Clinical 
Research (CEIC) which will make its ethical evaluation 21,22. 
The Portuguese Commission of Data Protection (CNPD) is a National Commission responsible 
for authorizing the processing of personal data and supervise data confidentiality and respect 
for human rights 22,23. 
According to the data available on INFARMED website, the number of clinical trials 
submissions in Portugal had gradually declining until 2011, outlining a slight increase from 
there, while the approval time decreases, as represented in Figure 4 24.  
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Figure 4 - Submitted Clinical Trials for authorization (2006-2015) – from INFARMED website 24. 
 
The Clinical Research law may be one of the factors responsible for the reduction of the 
authorization time observed between the year 2014 and the 1st half of 2015 24. 
There has been an effort by regulatory authorities to reduce the time of approval in order to 
promote the development of clinical research in Portugal. Despite the approval time has been 
decreased that remains to be seen as a foreign negative point by sponsors. 
According to the INFARMED website, the Table 1 represents the distribution of clinical trials 
submissions by the different clinical development phases. Since 2006, the majority of 
submissions corresponds to Phase III. The best years for clinical trials Phase I were 2013 and 
2014, were submitted a total of 10 trials, the largest number since 2006 24. 
 
Tabela 1 - Clinical Development Phases of Clinical Trials submitted since 2006 – adapted from INFARMED       
website 24. 
Development 
Phase 
2006 2007 2008 2009 2010 2011 2012 2013 2014 
1st Semester 
2015 
Phase I 2 7 3 6 2 6 3 10 10 3 
Phase II 20 30 31 27 17 19 25 20 24 11 
Phase III 104 74 100 73 79 58 82 75 81 39 
Phase IV 27 21 12 9 9 5 8 9 12 5 
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The law 21/2014 of 16 April regulates Clinical Investigation, including the arrangements for 
conducting clinical trials of medicines for human use, due to the transposition of Directive 
2001/20/EC, and the regime of clinical research of medical devices resulting from the partial 
transposition of Directive 2007/47/EC of the European Parliament. 
The Clinical Investigation Law creates a new framework for research with human beings in 
Portugal. It promotes transparency in scientific activity, from submission, advices, results, used 
instruments and data, facilitating the creation of research networks. 
The creation of the National Network of Ethics Committees for Health (RNCES) ensures the 
application of ethical evaluation to all clinical research and all kinds of studies 22,25. 
The creation of the National Register of Clinical Trials (RNEC) of public consultation 
promotes mandatory public register of studies, advices, authorizations, as well as support 
material and dissemination of studies. This public disclosure contributes to the non-repetition 
of studies 22,25. 
Submission process, assessment and standards of good practice become clear and expeditious 
contributing to reduce approval times and opinions by different entities, specifically the CEIC, 
INFARMED and CNPD.  
This law promotes increased responsibility of all clinical research stakeholders and represents 
a big improvement opportunity to Clinical Research in Portugal. 
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3. RESEARCH NURSING ACTIVITY 
 
3.1 RESEARCH NURSE SKILLS AND COMPETENCES 
 
Research is an important and vital aspect of health care, being essential for the provision of 
safe and effective health care and social assistance. 
The name “research nurse” has been commonly applied to nurses that work in a clinical 
research environment 26. The clinical role of research nurses has been more common in 
oncology clinical trials, maybe because these trials involve subjects who need long and 
complex treatments. The research nurse job is complex, varied and stimulating. 
During the research for the development of this project, I found several descriptions of 
competencies and research nurse's responsibilities, finding as well research nursing specialty 
area, with defined fields of action. 
According to American National Institutes of Health Clinical Center “The domain of practice 
for the specialty of clinical research nursing includes care provided to research participants, as 
well as activities to support protocol implementation, data collection and human subject 
protection” 27. 
As the clinical research expands, it is critical to emphasize the important role of clinical 
research nurses. They assure appropriate clinical care to research participants, ensuring their 
safety and welfare, the continuous accomplishment of the informed consent and the integrity 
and accuracy of collected data. 
The way the American National Institutes of Health Clinical Center describes the acting areas 
of research nurse is very structured and well defined, so I make a brief reference to some 
concepts that are part of the daily practice of the research nurse. In 2007, the American 
National Institutes of Health Clinical Center defined a scope of the Clinical Research Nurses 
(CRN) specialty including two nursing roles 27: 
The CRN: clinical nurses that support study implementation with a central focus on care 
delivery to research participants. 
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Research Nurse Coordinators (RNC): nurses responsible for study implementation and 
coordination, data management and compliance with regulatory requirements. 
According to the American National Institutes of Health Clinical Center, the clinical research 
nursing practice include five dimensions and each one include a set of activities that overall 
describe the specialty practice, as represented in Figure 5. 
 
 
Figure 5 - Clinical Research Nursing Dimensions, according to the American National Institutes of Health 
Clinical Center 27.  
 
Clinical Practice Dimension refers to nursing care and support provided to clinical research 
participants. Nursing care are determined by the clinical condition of the patient, study 
protocol requirements and clinical effects caused by the study procedures. 
Study Management Dimension refers to management of clinical and research activities to 
ensure clinical needs and patient safety, accurate data collection and protocol integrity. 
Care Coordination and Continuity Dimension, related with coordination of clinical and 
research activities according to clinical needs, requirements to complete the study and manage 
the link with primary care providers. 
Human Subjects Protection Dimension deals with the informed participation of clinical 
research participants, coordinating research activities in order to minimize subject risk. 
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Contributing to the Science refers to research nurse contribution as a research team member 
to the development of new ideas for study, exploration of new findings and innovation to 
improve the practice, patient outcomes and data collection accuracy. 
The list of what a research nurse could be doing is quite extensive. CRN play a central role on 
providing safe and quality care to research participants. They should have an extensive 
knowledge of good clinical practices, a good understanding of the study, the regulations and 
legislation to support protocol implementation, data collection and human subject protection, 
within the context of the care delivery. Along with clinical knowledge and judgment, their 
combined training gives these nurses insights and unique abilities in research activities 27. 
A research nurse are motivated by challenges, have initiative and the ability to effectively meet 
challenges, be adaptable and have the flexibility and skills necessary to handle with research 
activities of varying complexity, having as well leadership and excellent organizational skills. 
They must be accurate, pay attention to details, have meticulous approach, have the ability to 
read, analyze and interpret technical procedures such as protocols, informed consent 
documents and regulatory documents and have a high level of integrity. 
These professionals must have highly developed skills in research activity. Nurses are vital to 
maintain the accuracy of the data collection in research studies. Provide clinical support and 
guidance in research studies development 28.  
The results of a research project may be severely compromised if the protocol is not followed 
exactly on the day of procedures, for example, if the participants do not receive the correct 
dose, or samples are not collected in a timely manner and to the correct subject. 
A research nurse as good communication and negotiation skills, maintaining good 
relationships with colleagues, working always in a transparent manner, with high standards of 
professional integrity, using resources and skills enabling successful outcomes. 
Excellent communication skills are extremely important. Research nurses must be able to 
effectively communicate with scientists, physicians, researchers, corporate executives and 
often communicate complex information to patients / healthy volunteers groups according to 
their understanding. Nurses need an ability to interpret complex information, give clear 
explanations, along with excellent communication and interpersonal skills 29.  
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Skills to identify potential obstacles and solutions and the capacity to solve problems, planning 
short and long term strategic objectives, allow efficient management of costs and time. 
The research nurse should be able to work alone, being able to prioritise and to make 
decisions, staying motivated and responsible, and at the same time be part of a highly qualified 
team of motivated and respectful professionals with common goals. They must be able to 
perform multiple tasks in a timely manner, and work efficiently under pressure. They also must 
have general computer literacy, especially in the use of word processing, spreadsheets, 
database and presentation software, and the ability to undertake internet searches 30. 
Research nurse must be a critical thinker and have an analytical approach to problem solving, 
being flexible and able to manage multiple clinical trials (sometimes simultaneously) and 
function independently, performing diverse clinical duties.  
 
3.2 RESPONSIBILITIES OF A RESEARCH NURSE 
 
The research nurses involved in a research project have a quite extensive list of 
responsibilities. They have responsibilities that can only be exclusively made by nurses and 
other activities, which in many research centers, may be shared with other professionals, such 
as Clinical Trial Assistants (CTA) or Clinical Study Coordinators (CSC). 
To be easier to transmit and realize the different activities performed by research nurses, it will 
be described in context of different moments of the development and implementation of a 
clinical trial. 
 
Protocol development 
The first stage of a research project is the development of a study protocol, that includes the 
study objectives, how will be measured, clinical procedures required, what time points, what 
clinical data will need to be collected. 
There is a team involved in the protocol development, but it is really important include 
research nurses at this stage. They provide nursing expertise to the research team during study 
 23 
 
development and implementation. They know patients, care requirements and they have 
invaluable knowledge and experience to help researchers gather the information they will need 
to draw conclusions from the study. Research nurses could help to evaluate if the demands are 
too great or the criteria for inclusion too strict, it may be difficult to recruit patients or they 
may want to abandon the study before it finishes. It is important to obtain a good balance 
between the needs of the research and the research subjects involved. 
 
Study submission/Approvals 
In Portugal, before the beginning of any study, it is required approval by INFARMED, CEIC 
and CNPD. Some research nurses have the responsibility of completing these application 
forms and submit them to the competent authorities for review and approval. 
 
Patient Recruitment 
After study approval, patient recruitment is often the responsibility of the research nurse.  
Research nurses spend a good part of their time, identifying potential patients for a study or a 
clinical trial. They may screen hospital notes or during the multidisciplinary team meetings to 
highlight which patients are suitable for which study. 
They also have an important role in the recruitment of healthy subjects, enrolment and 
scheduling study visits. 
 
Informed consent 
Informed consent is a critical ethical component of conducting research in human subjects, and 
it is essential before participation in any type of research. The informed consent is a legal 
document that inform study subjects about their rights, the purpose of the study, describes all 
study procedures, potential risks and benefits, and alternative treatments. Subjects must 
participate in the study willingly, and vulnerable populations must receive extra protection 31. 
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The informed consent form (ICF) must be written in language easily understood and must 
provide enough information so that the subject can decide whether or not to participate in the 
study. 
Often research nurses are involved in the writing of informed consent form, as well as, in the 
verbal discussion with research participants. They know how to speak to patients or healthy 
volunteers in a way that allows them to understand complex scientific and medical 
information, explaining participants responsibilities, benefits and potential risks of the study. 
The explanation of data protection and share of on-going information regarding the study is an 
important part of the discussion of the informed consent process and could be responsibility of 
the research nurse. 
Research nurse should be patient advocacy. The rights, safety and wellbeing of research 
participants are the most important considerations and must prevail over the interests of 
science and society 27. 
Research nurses collaborates with physicians in determining eligibility of patients for clinical 
trials, cooperating with investigators on the review of inclusion and exclusion criteria. During 
clinical trial development, they work directly with the physician/investigator and clinical staff 
to ensure the completion of all study procedures and protocol compliance. 
 
Clinical Procedures 
Research nurses perform clinical procedures required by Protocol, providing direct nursing 
care to research participants, performing assessements and interventions related with studies. 
They also administers treatments and the research compound, perform specimen collection 
attaching great importance to proper sample collection and handling, and the timely execution 
of every study procedures. 
Collection of samples at specific time points, the accuracy in the fulfilment of the times and 
proper care of these samples during processing and storing are of utmost importance. 
In many research centers, lab skills are often undertaken by research nurses. After processed, 
samples will be stored for later analysis and determine the outcome of the study. Samples 
integrity is essential for taking conclusions with confidence. 
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The safety and well-being of research participants should be the top priority in clinical trials. 
Research nurses must have proper skills that allow them to early identify AEs, act in 
immediate and appropriate way, ensuring the safety and welfare of the participant.  Timely 
reporting of AEs is fundamental to patient protection and a responsibility of the research nurse. 
 
Data collection and Data entry 
The research nurse monitors the patients or healthy volunteers recruited to the clinical trial. 
During the treatment, they assure that subjects attend all necessary visits according to protocol 
and that all data is collected at each visit, assuming responsibility for clinical trial 
documentation. 
Another important aspect of data collection is the report of AEs. The report should be done in a 
clear and fast way, especially when they are more serious. The balance between effectiveness 
of a drug and its side effects should demonstrate that benefits must outweigh the risks.  
The data collected in a clinical trial should be complete and accurate, and data entry must be 
done in a timely way. Without accuracy in the compliance to a protocol and data collection, a 
study is not worth the efforts of all involved, including trial participants who gave their time 
and themselves. Activities of Quality Assurance should be performed to assure data integrity. 
Data collection should be performed based on study endpoints. The research nurse has the 
responsibility of completing accurately source documents and could assist the study 
coordinator with data transcription onto the case report form (CRF). 
 
The research nurse is often the point of contact for patients, answering patient questions, since 
the initial enrolment in the study until they finish the clinical trial. During the study, the 
research nurse has to make screening phone calls from patients with complaints, and must have 
the knowledge and confidence to deal with such calls, with maximum efficiency and safety, 
and referencing patients to other members of the care team when it deems appropriate. 
The nursing team must be trained and educated in the standard nursing research procedures, 
their practice must be in compliance with principals of Good clinical practice (GCP), 
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regulatory requirements, study protocols and internal SOPs of the research unit. The research 
nurse should disseminate clinical knowledge and best practices related to clinical research 
through interactions with nursing colleagues, presentations or publications. 
Provide teaching to research participants, patients or healthy subjects and family about 
participation in the study, their clinical condition or disease process. 
Monitor and assure the research participant safety and report potential AEs, drug interactions 
and the overall efficiency of the medication. 
Record research data (example: vital signs, administration of investigational medicinal product 
(IMP), participant responses, etc.) in approved source document or clinical report forms, if 
applicable. 
The senior research nurses should behave as experts in a specialty area and participate in the 
query and analysis of research data.  They should disseminate clinical knowledge and best 
practices related to clinical research through interactions with nursing colleagues, 
presentations, meetings or publications. They should mentor junior colleagues and students 
participating as members of the research team. 
 
3.3 RESEARCH NURSE IN THE MULTIDISCIPLINARY TEAM 
 
A multidisciplinary team involves a range of health professionals, working together to deliver 
comprehensive patient care, addressing patient's needs as much as possible. As the clinical 
condition of a patient changes over time, the composition of the team may change to meet the 
medical and psychosocial needs of the patient. To ensure best functioning of the team and 
effective outcomes, the roles of the multidisciplinary team members must be clearly defined. 
Research nurse cooperates and works in a wide variety of clinical specialties, identifying the 
most appropriate information and collaborating with the investigators to ensure that each study 
is conducted safely and accurately according to the protocol. It also assists investigators 
developing prescriptions and data collection tools. Working with other researchers and the 
multidisciplinary team is fundamental for successful research. The effectiveness of the team is 
the total sum of their individual efforts. 
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Research nurses work within the care teams, assuring the studies maintain visible to the 
multidisciplinary team and to the patients. The challenge is to use every opportunity to dissolve 
the barrier between care and research, trying integrate the two, so as to deliver excellence in 
healthcare 30. 
Research nurses coordinate interdisciplinary meetings and activities in the context of a study 
and coordinate research activities to minimize subject risk. They act as a key link in the 
communication network within the multidisciplinary team, and effective communication is 
essential in the clinical trials. 
Most clinical research involves not only the multidisciplinary team of nurses, doctors and other 
professionals in the local site, but also external organizations which otherwise might be 
involved with the research. The research nurse needs to liaise with a variety of different 
individuals to facilitate the smooth running of the trial and to achieve the best results, assuring 
the management of time and costs and the collection of accurate and reliable data. 
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4. CLINICAL TRIALS EXPERIENCE IN A PHASE I UNIT 
 
4.1 BLUECLINICAL PHASE I UNIT 
 
Blueclinical Phase I unit conduct studies in healthy subjects and is located at the third floor of 
Prelada’s Hospital, Porto.  
Blueclinical Phase I Unit organization is schematized in the organogram in Figure 6. 
 
 
 
Figure 6 - Blueclinical Phase I Organogram 32. 
 
MP-Managing Partner; QA-Quality Assurance; HRA-Human Resources and Administration; SF-Support Functions (IT, 
HR, Administration); COD-Clinical Operations Director; CRM-Clinical Research Manager; CD-Clinical Director; 
PHM-Pharmacy Manager; CTA-Clinical Trials Assistants; LM-Laboratory Manager; LT-Laboratory Technicians; 
RNC-Research Nurse Coordinator; RN-Research Nurses; PI-Principal Investigator; RP-Research Physicians; BDM-
Business Development Management; DSM-Drug Safety Management; REG-Regulatory Affairs Management; MED-
Medicines Unit; MDV-Medical Devices Unit; PM-Project Management; MWR-Medical Writing and Reporting; DM-
Data Management; STA-Statistics; PKM-Pharmacometrics. 
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The clinical and scientific team has experience in varied types of studies for the global market, 
both with generics (bioavailability/bioequivalence) and innovative medicines. 
The clinical and scientific team is composed 2 Clinical Pharmacologists, 8 Research 
Physicians, 22 Research Nurses, 3 Laboratory Technicians, 2 CTAs and 1 Pharmacist. Some 
collaborators have more than 10 years of experience in phase I studies. 
Blueclinical Phase I unit, for being located in the hospital, has access to immediate medical 
support in case of emergency, accredited clinical laboratory and imaging for safety tests and 
logistic services.  
Phase I unit has restricted access with electronic system and facilities include: 
 34 adjustable beds, distributed by seven quadruple rooms and three double bedrooms; 
 For safety reasons, the rooms have an internal window that allow permanent visual 
monitoring of trial participants; 
 Several bathrooms and showers; 
 Dining and living room for volunteers; 
 All bedrooms, dining and living room have cable television. All unit are equipped with 
wireless internet; 
 Emergency call system to use in case of emergency, in bedrooms, bathrooms and 
showers; 
 A pharmacy with electronic restricted access to necessary staff. The room has 
protection of direct light and control of temperature and humidity. 
 The laboratory is equipped with appropriated equipment to perform sample processing. 
 The storage room, near the laboratory, has electronic restricted access to necessary 
staff and is where are located the freezers (-20°C / -80°C) for sample storage. The 
room is protected from direct light and has temperature control. Electrical outlets of 
this room have access to a back-up generator in the event of power failure; 
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 The nursing room is appropriately equipped with sample collection chairs and clinical 
equipment and supplies necessary to perform clinical procedures; 
 The emergency cart is located in strategic position in the corridor to allow immediate 
movement in case of emergency; 
 A physician office with clinical equipment to perform medical appointment and 
clinical examination; 
 A management office and a coordination office. 
Phase I unit contains the required clinical equipment to perform clinical procedures according 
with required with Protocols and Blueclinical Standard Operating Procedures (SOP).  
 
4.2 EXPERIENCE AS RESEARCH NURSE  
 
In 2013, I start working at Blueclinical, in part-time, as RNC and in the same year I started the 
Training Programme in Pharmaceutical Medicine, at Aveiro University. 
Despite having a few years of experience in clinical trials, the knowledge acquired at the 
Training Programme in Pharmaceutical Medicine is huge. When administering a medicinal 
product had no idea of the amount of years of research and the costs involved until the 
introduction of the new drug on the market.  
In 2014, I leave the hospital and begin full-time functions in Blueclinical as RNC.   
 
EXPERIENCE AS RESEARCH NURSE COORDINATOR 
 
Nursing team coordination 
As RNC I lead, organize and manage Blueclinical Phase I nursing team, ensuring adequate 
training and qualifications, in compliance with applicable legal and regulatory requirements, 
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clinical trial protocols (CTP), Blueclinical Standard Operating Procedures (SOPs) and ICH 
Good Clinical Practices (GCP). 
As responsible of the training process of the nursing team I provide training and assure the 
development of clinical SOPs related with nursing practice, in order to standardize nursing 
activity. Re-education of nursing team could be necessary according with evaluation of their 
performance.  
It is also my responsibility the recruitment, interview and selection of new staff to integrate the 
nursing team. 
 
Quality assurance 
As Research Nurse Coordinator collaborate with Quality Assurance Department developing 
appropriate action plans for quality improvement. 
SOP is a set of information and written instructions that document a procedure or activity in 
order to perform it properly and consistently, reflecting the activity followed by an 
organization. SOPs minimizes variation of procedures and promotes quality through 
consistency even if there are personnel changes 33.  
The development and use of SOPs are an important step of a successful quality system. SOP is 
not rigid, can be updated and I am responsible for reviewing the SOPs concerning to nursing 
procedures and assure their suitability to practice. 
Evaluate nursing performance and ensure that nursing team guides its practice in a 
standardized way, according to defined in SOP. 
 
Audits and inspections 
Blueclinical is a growing company and qualification audits are becoming a common situation 
in daily life of the company. The purpose of these audits is to evaluate the company in order to 
establish partnerships. These visits are very complete and include presentation of Blueclinical 
services, facilities tour, interviews to some collaborators, consulting of documents as SOPs, 
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templates of medical documentation and source documents, site qualification documents (CVs, 
training and qualification records of staff), laboratory and equipment documents. 
After an audit the company writes a visit report, making observations about situations, negative 
or positive, which it considers relevant. After an inspection will be issued a document 
reporting the findings found. 
As member of the clinical team I collaborate in internal and external auditing, inspections, 
qualification visits, activities preparation and in the implementation of eventually necessary 
Corrective Action Preventive Action (CAPA) plans. 
 
Consultant 
My collaboration as a consultant began in the elaboration of structural plan of Blueclinical 
Phase I Unit. I and other members of the team, as the Clinical Director and Clinical Research 
Manager, were invited to meet the infrastructure and give opinion in order to get the best 
structural design for the new Phase I unit, taking into account the previous work experience. 
After completion of the project, it was necessary to equip the entire unit with appropriate 
clinical equipment and supplies for the beginning of activity and to the normal operation of the 
Unit. It was a gratifying experience, start a project and see it grow is always a major focus of 
motivation. 
The protocol is developed by a team, and sometimes my collaboration is required as a 
consultant on issues related to clinical practice, collaborating in the protocol design in terms of 
planning of clinical procedures. 
 
Emergency Cart maintenance 
The best strategy to deal with an emergency is to be prepared before it happens. For this 
reason, Blueclinical Phase I Unit is prepared with clinical staff trained and qualified in 
emergency, with an emergency cart, immediate medical support of the Hospital in case of 
emergency and availability of vacancies in the Intensive Care Unit. 
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The emergency cart is equipped with defibrillator monitor, emergency equipment, rescue 
medication and oxygen. The material is organized to allow intervention in case of life-
threatening due to impairment of respiratory, cardiac or neurological system, allowing to act on 
the airway, breathing, circulation and neurological dysfunction. 
I am responsible for the maintenance of the emergency cart and rescue medication together 
with the research pharmacist.  
The emergency cart is sealed and this seal is checked daily to assure that all equipment is 
according the last review.  
All equipment and supplies are verified monthly to check their conditions and expiry dates. 
The defibrillator monitor is tested monthly to assure the proper function, and is calibrated for 
an external company at least once a year. 
This procedures are described in SOP and must be recorded in appropriate documents. 
 
Work plans and Nursing Schedule 
As Coordinator of the nursing team I collaborate with Project Manager on the performing of 
Master Work plan. This plan contains all the procedures to be performed individually to each 
volunteer, as required by the protocol. After preparation of this plan, it is possible to determine 
the staff number necessary to perform all the clinical trial procedures, for example, the number 
of Physicians, Nurses, Laboratory technicians or CTAs. Besides the calculation clinical staff, 
also allows to perform the work plans of each team member. 
During the clinical trial, the work plans are used to guide each team member, defining the tasks 
and procedures necessary to perform. 
To assure the plan is well designed, these documents are subjected to rigorous quality control 
process, made by different person. A small mistake in these documents can lead a big deviation 
from the protocol. 
I also have the responsibility of performing the Nursing shifts schedule. When developing the 
nursing schedule I always have the concern to balance the number of Junior and Senior nurses. 
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The Senior Nurses have more experience in clinical trials and are qualified with advanced life 
support course. Senior Nurses are present in all confinement period of the clinical trial. 
 
Equipment and stock management 
Every clinical trial needs preparation, namely in what refers to clinical equipment and 
materials. The overall clinical equipment must remain properly calibrated and verified, taking 
into account their specificity and needs. As for the clinical supplies, the stock needed for each 
clinical trial is calculated according with the specifications of each protocol, for example, 
number of volunteers, number of confinement periods, number of required blood samples or 
the need for electrocardiograms (ECGs), ensuring that sufficient and proper equipment and 
material are available to the conduct of the clinical trial. 
Selection of clinical supplies and equipment necessary for the proper functioning of the unit 
requires research, contact with suppliers and budgets management, in order to obtain the 
desired product at the best price. 
It is my responsibility to assure the management of clinical supplies and clinical equipment, 
ensuring its good conditions, maintenance and stock.  
 
EXPERIENCE AS RESEARCH NURSE 
Besides the coordination of the nursing team, I also have the research nurse functions. During 
the development of a clinical trial there are a lot of activities that could be done by a research 
nurse. I had the opportunity of developing the following procedures and responsibilities during 
my professional activity. 
 
Investigators Meeting  
After authorities approval and before every trial initiation it is necessary to organize and 
conduct the investigators meeting to assure that all team, clinical and non-clinical, has the 
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appropriate training in the clinical trial protocol about to start. Besides this training, the team 
must have their training in GCP and SOPs updated. 
At the meeting, the clinical trial protocol will be presented in detail, addressing the study 
objectives, the IMP to be tested, eligibility criteria, randomization and enrollment procedures, 
clinical procedures during the trial, safety assessment and AEs monitoring and report. The 
source documents, electronic case report forms (eCRFs), and instructions for completing will 
be presented to. During this meetings can be clarified doubts about the trial and discussed 
opportunities of improvement. 
 
Volunteers recruitment 
Before volunteers recruitment, a recruitment memorandum is prepared with Protocol and 
informed consent information, to be used as a guide during the recruitment phone call and to 
present information about the trial. 
Blueclinical Phase I has an online database (approved by CNPD) where candidates to 
volunteer can do their registration and fill some personal information. Volunteers can only be 
selected from this database. 
During recruitment, a screening visit is scheduled to assess volunteer healthy condition and 
evaluate volunteer eligibility. 
 
Informed Consent  
Before the screening process, the volunteer will be informed about the study, specifically about 
its end points and participation risks.  All doubts about the trial will be explained and the 
volunteer can decide in a free way if he/she wants to participate in the clinical trial. The 
decision is consummated with the signing of ICF. 
As research nurse, I can support research physician obtaining the informed consent, according 
to protocol, SOPs and regulatory requirements and review of the informed consent form 
signatures. 
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Screening  
The screening goal is to assess and document volunteer healthy condition and evaluate 
volunteer eligibility. 
The screening visit comprise a medical appointment which includes demographic data, vital 
signs, medical history and physical examination. After medical appointment the following 
exams are performed by the research nurse: ECG, blood samples  to hematology, biochemistry, 
coagulation, viral serology (Human Immunodeficiency Virus (HIV), hepatitis B and C) and 
serum pregnancy test (if woman). Urine is collected to urinalyses and to test drugs-of-abuse, 
and it will be performed an ethanol breath test. Additionally, it may be performed more 
laboratory tests if required by protocol. 
The volunteer eligibility is only finalized after evaluation of the laboratory results, by the 
Principal investigator or the authorized research physician. 
After eligibility completion, the volunteer is informed by phone that can proceed to admission, 
this contact can be performed by the research nurse. 
 
Admission 
Admission occurs on the day before of the dosing day. At this moment, it is performed a 
review of selection criteria, medical history and physical examination update, by research 
physician. The research nurse will be responsible to perform ethanol breath test, assessment of 
vital signs and urine collection to test drugs-of-abuse and pregnancy test in woman. After 
assessing all results, the research physician randomize the volunteers that accomplish all 
requirements to participate in the clinical trial and starts the confinement phase. 
In Phase I Unit, after randomization, the volunteers will be identified with a bracelet which 
will include the number of randomization and initial of his name. It will be assigned a uniform 
to use in the unit and will be assigned a bed according to their number. The belongings will be 
stored in a locker with a key. 
All unit rules will be explained as well as all procedures that will be performed so that the 
whole process of confinement runs smoothly. 
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Confinement phase 
All volunteers stay confined at the clinical research facilities under the same conditions. Diet 
and fluids are standardized, meals and snacks are identical in all periods and provided 
according with times defined in Protocol. 
According with randomization code, volunteers are assigned with treatment sequence defined 
in Protocol, and the IMP can be administered by research nurse or research physician, after an 
overnight fasting or after a high-fat and high-caloric breakfast. IMP administration is a critical 
procedure and according with SOP, is made under supervision of a witness that could be 
another research nurse, a research physician, a Research Pharmacist or a CTA. 
Blood samples are collected by research nurse, at selected times, to determine plasma 
concentrations. The assessment of vital signs can be done by research nurse or research 
physician, at times defined on Protocol. 
All the procedures, as meals, IMP administration, blood samples collection and vital signs 
assessment are made under strict compliance with the time set for their achievement. 
Blood samples are centrifuged, processed and storage by a Laboratory Technician, and later 
are transported to a biolaboratory to be analysed. 
 
End of Study and Follow up 
At the end of the study some procedures are repeated for safety reasons and to document that 
health condition of volunteer maintains. 
Research nurse perform vital signs measurement and collect blood for hematology, plasma 
biochemistry and serum pregnancy test, in woman.  
Research physician updates AEs and if safe, authorize discharge from the confinement phase. 
After discharge may be necessary to return for additional blood samples or other follow up 
test. 
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Safety procedures and AEs monitoring 
AEs must be monitored since the moment volunteer gives the informed consent until the end of 
the study. The ongoing AEs must be monitored until they are resolved or when it is not 
medically justifiable to continue the follow-up. 
Research physician must categorize AEs according to seriousness, severity, causality, action 
taken on study medication and outcome. 
Research nurse identify, document and monitor AEs in coordination with research physician 
and other team members and provide treatment as indicated by research physician. 
When applicable, provides medical care in compliance with clinical trial protocol and ensures 
volunteers safety. 
Research nurse, has Advanced Life Support knowledge and the Unit has an emergency cart 
with appropriate equipment and rescue medication to use in case of need. 
At the same time, the Phase I Unit has the collaboration of the hospital's emergency team. This 
team is activated by the hospital's internal telephone number 222 and moves to the place where 
there was the medical occurrence and provide emergency medical care. 
 
Source documents and eCRF completion 
During the clinical trial, all clinical data related to each volunteer is recorded in the source 
documents. Clinical assessments, clinical procedures and AEs, if any, should be rigorously 
reported, in an accurate way, to allow the correct interpretation of data and reliable results. 
This documents must be structured according to clinical trial protocol requirements, in order to 
collect all relevant information necessary to complete the final Clinical Study Report (CSR). 
During my practice as research nurse I assure adequate completion and timely update of source 
documents. Besides this, I monitor and perform quality review to source documents to assure 
data accuracy and if all fields are completed, signed and dated, by the other members of the 
team. Source documents information must be compliant with the Protocol and GCP’s 
guidelines.  
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The source documents must be in order and updated, reflecting always the latest study 
observations allowing, if necessary, to recreate what happened in a specific situation. Source 
documents will be subjected to quality auditing by trial Monitors. 
Data from source documents are transcribed to electronic format, eCRFs, into a computer 
database by the clinical research staff, where I am included. Each user has a username and a 
password associated, so all data entry can be easily traced. During data entry process it is 
possible to perform quality control and reconfirm the data consistency, having advantages over 
the paper, like reminders for inconsistencies, missing responses or invalid data. 
Data entry could be an easier process if data was recorded directly in an electronic format, 
there would be no duplication of information, could minimize the risk of transcription errors 
and reduce the amount of work dispensed with this task. 
 
Other activities 
IMP individualization is responsibility of the research Pharmacist, but for being a critical 
procedure and by SOP is done in the presence of a witness. During the clinical trials, for 
several times, I assume the role of witness.  
Many activities conducted in phase I unit are subjected to quality control in which I participate, 
for example, in quality control of the labels of blood collection tubes, the IMP vial, working 
plans, etc. 
 
4.3 RESEARCH NURSE ACTIVITIES IN AN ONCOLOGICAL PHASE I/IIA TRIAL 
 
During my activity as research nurse in Blueclinical, I also have the opportunity to work with 
oncological patients, in an Interventional phase I/IIa clinical trial, specifically with patients 
with advanced head and neck cancer. 
The standard treatment for this cancer involves the use of radiotherapy, chemotherapy and 
surgery. This clinical trial is indicated for those patients that do not have any additional anti-
cancer treatment. The advanced head and neck cancer is one of the most unpleasant and 
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agonizing way the person may die. The rapid deterioration of disease becomes unbearable 
because of visible, odorous, and tumours or metastasis fungating. 
The study indication is to investigate the tolerability, pharmacokinetics and anti-tumour effect 
of photodynamic therapy (PDT) in patients with advanced head and neck cancer.  
PDT is a treatment approach of cancer that consists on the administration of a photosensitiser 
drug, injected into the bloodstream, which is absorbed by cells all over the body. The 
photosensitiser is activated on the tumour target area, by a laser light of a specific wavelength, 
and produces an active form of oxygen that destroys nearby cancer cells. In addition, the 
photosensitiser can damage blood vessels of the tumour thus preventing the cancer from 
receiving necessary nutrients and also may activate an immune response toward cancer cells 34. 
This clinical trial is conducted in an Oporto hospital, and PDT session is performed in the 
operating room. PDT session is performed in asepsis environment, under light protection, 
under anaesthesia and vital signs monitoring. During PDT session, I have the opportunity to 
make the specific clinical procedures as calibration of the laser and respective optic fiber and 
administration of the photosensitizer drug. Knowledge and practice in emergency care are 
needed in case of anaphylactic reaction.  
The other clinical procedures required by protocol consists on collection of blood samples for 
safety and pharmacokinetic analysis, urine samples for urinalysis and pregnancy test, weight 
measurement and patient's height, assessment and monitoring of vital signs, ECG, 
photosensitivity skin tests, photographs and update of the physical examination of the tumour 
target area, patients monitoring to magnetic resonance imaging (MRI) and demarcation of 
tumour target area in order to be located in the imaging, and continuous AEs monitoring. 
In this patients, subjected to various chemotherapy treatments, veins may become hard, 
sclerosed and fibrosed, and peripheral venous access can be difficult to obtain. 
Patients with head and neck cancer usually have invasive tumour lesions, quite extensive and 
exudative, being necessary to carry out specific dressings and care.  
The tracheostomy and percutaneous endoscopic gastrostomy (PEG) are quite common in these 
patients requiring nursing specific expertise in handling them in order to prevent complications 
or their early identification. 
 42 
 
All my clinical experience, knowledge and the at ease in the hospital environment are 
extremely important and useful to allow me to perform the specific procedures required by 
protocol and at the same time provide oncologic care to this patients assuring their safety and 
wellbeing. 
During implementation and trial development is necessary to provide education and support to 
clinical staff, patients and family. 
I also collaborate with Research Physicians obtaining the informed consent and determining 
eligibility of patients for the clinical trial.  
I also perform electronic data entry in CRFs, monitoring activities, including revision of source 
documents, maintenance of project files, assume responsibility for clinical documentation and 
plan the requirements for clinical trial material and equipment.  
I ensure that clinical procedures and Protocol development are in compliance with principles of 
Good Clinical Practice, Protocol, applicable regulatory guidelines and adheres to Ethical 
principles. 
Participate in this clinical trial is rewarding because the cancer of head and neck is disfiguring 
and progress rapidly toward a fatal conclusion. Time is the most limiting factor, the clinical 
condition of these patients worsens rapidly, sometimes making it difficult to reach the effective 
dose in a very low lifetime. It is motivating to find an alternative treatment when existing 
treatments has nothing to offer. 
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5. DISCUSSION 
 
In my academic Nursing education and my clinical practice at the hospital I have no 
information about clinical trials or clinical research. My first contact with clinical research 
occurred when I started working as a research nurse in 1999. At this point I felt some 
difficulties because the knowledge in this area were very limited. My clinical knowledge was a 
valuable tool during the performing of clinical procedures required by protocol but, in some 
situations, the lack of a theoretical background was a disadvantage, becoming more difficult to 
understand some issues related with legislation or the product lifecycle. 
During my professional activity as research nurse, I learned many concepts and developed 
skills very useful in the clinical research area.  
Despite operating as research nurse for some years I felt need for a theoretical support that 
could help me to understand many practical procedures and know the huge reality of R&D, 
behind the clinical research.  
I recognize that before attending the Master in Biomedicine Pharmaceutical, I had many gaps 
in my education in terms of specific knowledge of this area. The knowledge obtained about the 
product lifecycle, since the discovery phase that could began with an original idea to the finish 
product used in real life, about legislation, the essential documents required before initiate a 
clinical trial, the submissions and approvals requirements, even the non clinical studies 
required to perform before a medicinal product could be tested in humans, are valuable and 
gave me a completely different perspective of what is the clinical research. 
The Master in Biomedicine Pharmaceutical brought together knowledge and development of 
technical competences and personal skills extremely valuable in daily activity as research 
nurse. The second year coincided with the beginning of my full time activity in Blueclinical 
and was very advantageous and effective to consolidate and relate the knowledge imparted in 
the master with practice. I began having perception of the amount of necessary tasks to 
accomplish before, during and after conducting a clinical trial. Before the trial, it is necessary 
to prepare the Protocol, ICF, financial contracts, insurance, submissions, volunteer’s 
recruitment, logistic trial planning, including cleaning services, catering services, human 
resources and clinical supplies and equipment. During the trial, the clinical procedures occur, 
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including blood samples collection and processing. During and after the trial it is necessary to 
review source documents, perform data entry on the eCRFs and begin to develop the CSR. 
During this period working full time, I developed my computer skills, organizational and 
planning skills. My past working in the hospital helped me to assess priorities and manage 
them as in the emergency department where everything is urgent, we learn to define what is 
emergent. I learned to organize the schedule and to have frequent meetings with the different 
stakeholders of the study. At this moment my field of activity is not so restricted, making it 
more motivating because I can perform different tasks. 
One of the difficulties is to realize that in clinical research there are multitasks to accomplish 
and at the same time, the work never ends. In hospital work is ongoing, when a nurse comes 
out, it is replaced by another which continues the work, and so on, and work are constantly 
being made. In clinical research, sometimes is difficult managing the timelines, because there 
are unexpected situations, urgent tasks that spend the time reserved for another task, leading 
occasionally to failure to comply with the deadline. 
Clinical research is developing in a quick way and it is extremely important that professionals 
working in this field have the best qualifications, so it is urgent to promote education and 
training of professionals who participate in it. 
The name “research nurse” has been applied to nurses who work in a clinical environment. 
Currently nurses often come into research settings without prior research training 30.  
Nurses are the fulcrum of clinical trials, they play an important role in clinical research, 
comparing to traditional nursing roles. They assure implementation and conduction of the 
protocol, guaranteeing participant safety. The specific clinical activities, skills and educational 
requirements necessary for nurses to implement and manage patient care in clinical research 
scenario are not well delineated. Besides, there is an absence of formalized role descriptions 
that connect nursing job titles to specific knowledge and competences essential when working 
in clinical research environments. With the increasing number and complexity of clinical trials, 
the definition of the roles and contributions of nurses specialized in clinical research becomes 
increasingly important, they can make important contributions to the integrity of research, 
patient care, care coordination and human protection. 
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Aspects such as clinical knowledge, be at ease in the hospital, the way they relate to other 
members of the multidisciplinary team and the provision of care to research participants, 
makes nurses an integral part of clinical research. 
During my professional activity as research nurse, I had some difficulties and found many gaps 
in academic and professional training of nurses, with regard to this specific area. These 
challenges allowed me to identify resources and competences that when group in a single 
source can be of used by other professional bourses to better begin working in this area. By 
describing the clinical practice of a research nurse, the necessary knowledge, skills, key 
responsibilities and activities in this area I hope to somehow help create a guide to other nurses 
who wish to pursue the area of clinical research. 
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6. CONCLUSION 
 
Clinical research is a vital aspect of the health service for finding new treatments, improve and 
provide effective and safe health and social care. 
Scientists, physicians, specialists, nurses, and other health professionals are the driving force 
behind medical research today. So, it is extremely important that professionals working in this 
field have the best qualifications. Nurses play an important role in clinical research, being 
related with implementation and coordination of research involving human subjects and with 
the care delivery, education, and advocacy of clinical research participants assuring they are 
protected and supported along the research study. They have a frontline role that puts them in a 
unique position to reflect the needs and concerns of patients/ research participants and the 
public 30. 
Nurses work in a wide range of roles to improve the health of the people, so it is very 
important that they have the appropriate education and training to ensure the quality and 
accuracy required on clinical research.  
The research nurse role is extremely interesting, dynamic and stimulating. A strong foundation 
based on years of nursing experience is crucial to the role, but it requires additional knowledge 
and competences. These should include management and organisation skills, communication, 
teaching and mentoring, general computer literacy and an understanding of the research 
process and terminology. It is crucial for successful research to work with other researchers 
and the multidisciplinary team. Without dedicated research nursing team it is difficult to 
succeed in clinical research.  
The development of this work contributed to organize and structure ideas with regard to the 
responsibilities and necessary competencies for clinical practice of a research nurse. The list of 
responsibilities is quite extensive and some of nurse's activities cover tasks that could be 
performed by other professionals such as CTAs, study coordinators, clinical research managers 
and even project managers. At the same time allowed me to have awareness of the encountered 
difficulties, training needs and the resulting benefits of attendance on the Training Programme 
in Pharmaceutical Medicine. 
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I hope that with this work, I have been able to transmit what is the clinical research, what skills 
are considered most important to research nurses, what are the main responsibilities and what 
kind of functions can be performed by nurses in clinical research. 
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